Στοίβες SARMs: Τι λέει η έρευνα για τον συνδυασμό ενώσεων, Ηνωμένο Βασίλειο 2026

Ενημερώθηκε τον Σεπτέμβριο του 2026. Το κατάστημα SARMs πουλάει μόνο ερευνητικές ενώσεις. Τίποτα σε αυτήν τη σελίδα δεν αποτελεί ιατρική συμβουλή ή οδηγία για ανθρώπινη χρήση.

Stacking is the most commercially popular idea in this category and the least supported by evidence. Every reputable source has to open a page on this subject with the same sentence, so here it is: no clinical trial has ever tested a combination of two or more selective androgen receptor modulators in humans. Not one. Every stack discussed online is an extrapolation built from single-compound studies, animal pharmacology and anecdote. This guide explains what the pharmacology does and does not imply, what the published case reports say about people who combined compounds, and what the bundles sold as research stacks actually are.

What a stack is

In retail terms a stack is simply a bundle of two or more research compounds sold together, usually at a lower combined price than buying each separately. In pharmacological terms it is a combination for which no interaction data exists. The two definitions are worth keeping separate in your head, because the first is a commercial arrangement and the second is a research question nobody has answered.

What the research does and does not contain

The single-compound record is reasonably good. Ostarine has phase I, II and III human data. LGD-4033 has a phase I safety and pharmacokinetic study (Basaria and colleagues, Journals of Gerontology, 2013). RAD-140 has a first-in-human oncology study (LoRusso and colleagues, Clinical Cancer Research, 2022). MK-677 has multiple trials including a two-year study in older adults (Nass and colleagues, Annals of Internal Medicine, 2008). Cardarine has short human trials of lipid and metabolic endpoints.

What does not exist is any study in which two of those compounds were given together and the result measured. There is no pharmacokinetic interaction data, no combined safety data, and no evidence that the effects add, multiply or interfere. The claim that a particular pairing produces better results than either compound alone has never been tested in a human being under controlled conditions.

The pharmacological rationale, stated honestly

There is a coherent theoretical argument for combining compounds with different targets, and it is worth setting out because it is the actual reason the practice exists.

Ostarine, LGD-4033, RAD-140, YK-11 and S-4 all act on the androgen receptor. Combining two of them means two ligands competing at the same receptor, so the theoretical case for additive benefit is weak while the case for additive suppression is strong. Combining an androgen receptor agonist with a compound acting elsewhere is a different proposition. MK-677 works through the growth hormone secretagogue receptor. Cardarine is a PPAR-delta agonist. Stenabolic targets REV-ERB. On paper these are independent pathways, which is the reasoning behind the common muscle bundles and cutting bundles.

That is a hypothesis, not a finding. It has never been tested. The honest summary is that the mechanisms do not overlap, and that tells you nothing about what happens to lean mass, lipids or liver enzymes when they are combined.

Additive risk, which has been observed

Where the evidence does speak is on the risk side, and it is not encouraging.

Suppression is dose-dependent for every androgen receptor agonist studied, so combining two of them means combining two suppressive stimuli. The phase I LGD-4033 data showed clear dose-dependence for testosterone, LH and FSH, and there is no mechanism by which adding a second agonist would reduce that.

HDL cholesterol fell in a dose-dependent way in both the LGD-4033 and enobosarm trials. Again, no reason to expect a combination to be gentler.

The liver signal is the most concrete. Barbara and colleagues, writing in ACG Case Reports Journal in 2020, described drug-induced liver injury associated with a product labelled as RAD-140 and a second product labelled as containing both RAD-140 and LGD-4033. Flores and colleagues described a case series of cholestatic liver injury associated with SARM products in Hepatology Communications in 2020. Combined products appear in this literature, and RAD-140 was the compound whose own clinical trial was limited by raised transaminases.

There is also a compounding argument that has nothing to do with pharmacology. Van Wagoner and colleagues found in JAMA in 2017 that only 52 per cent of 44 products sold online as SARMs contained the labelled compound. Buying four unverified products instead of one multiplies exposure to that problem fourfold.

What the stack products are

The bundles on this site are research bundles, not protocols. The Advanced Muscle Stack contains Testolone RAD-140, Ligandrol LGD-4033, Ibutamoren MK-677 and YK-11 Myostine, 90 capsules of each. The Advanced Shredding Stack contains Ostarine MK-2866, Andarine S-4, Cardarine GW-501516 and Stenabolic SR-9009, again 90 capsules of each. Beginner and intermediate bundles pair fewer compounds. All are manufactured in the UK and each batch is third-party tested.

What they offer is a lower price per bottle and the convenience of a single order with matching batch documentation. What they do not offer, and what we do not claim, is a validated combination or any guidance on how to use them. They are sold strictly as research material.

Νομικό καθεστώς στο Ηνωμένο Βασίλειο, 2026

None of the compounds in these bundles is controlled under the Misuse of Drugs Act 1971. Each is an unlicensed medicine under the Human Medicines Regulations 2012 if sold or advertised for human use, and the MHRA enforces that, which is why everything here carries a research-only notice. Bundling does not change the legal position of any individual compound. All of the androgen receptor agonists, along with Cardarine, Stenabolic and MK-677, are prohibited in sport under the WADA list, so a multi-compound bundle is multiple separate anti-doping violations waiting to happen.

Πώς να ελέγξετε έναν προμηθευτή

For a bundle, the test is stricter than for a single product. You should be able to obtain a batch-specific certificate of analysis for every compound in the box, not one certificate covering the bundle. Each should show identity by HPLC or LC-MS, a purity figure, and a batch number matching its own bottle. Add UK manufacture, clear per-capsule amounts, a research-only notice and verified-purchase reviews. Dexters Labs bundles are UK made and each component batch is independently tested, with certificates linked from the product pages.

Συχνές ερωτήσεις

Is there any trial evidence for SARM stacks? No. No human trial has tested a combination of two or more of these compounds.

Why do suppliers sell stacks then? Because customers ask for them and bundling is cheaper per bottle. We describe them as research bundles for that reason and make no efficacy claim.

Does stacking increase suppression? The pharmacology says it should, since suppression was dose-dependent for every androgen receptor agonist studied, but no study has measured a combination.

Which stack is best? That question cannot be answered from evidence, so we do not answer it. Anyone who does is guessing.

Is a stack with MK-677 different? MK-677 acts on a different receptor and did not suppress testosterone in its trials, so the mechanisms do not overlap. That is a rationale, not a result.

Is bridging supported by research? No. Continuous or overlapping use has never been studied in humans and the long-term safety data does not exist for any of these compounds.

Σχετική ανάγνωση

• Είναι ασφαλή τα SARM; Τι λένε τα στοιχεία για τις παρενέργειες
• SARMs and lean mass: what the trials actually showed
• SARMs and fat loss: what the studies measured
• PCT after SARMs: what the studies show

Ερευνητικό προϊόν: Dexters Labs Advanced Muscle Stack, four compounds

Sources: Basaria S et al., J Gerontol A Biol Sci Med Sci 2013;68:87-95. Dalton JT et al., J Cachexia Sarcopenia Muscle 2011;2:153-161. LoRusso P et al., Clin Cancer Res 2022;28:4831-4841. Nass R et al., Ann Intern Med 2008;149:601-611. Barbara M et al., ACG Case Rep J 2020;7:e00409. Flores JE et al., Hepatol Commun 2020;4:450-452. Van Wagoner RM et al., JAMA 2017;318:2004-2010. WADA Prohibited List 2026.